

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
29 July 2004 (29.07.2004)

PCT

(10) International Publication Number
WO 2004/062620 A2

541.952
12 JUL 2005


- (51) International Patent Classification⁷: **A61K**
- (21) International Application Number:
PCT/US2004/000754
- (22) International Filing Date: 13 January 2004 (13.01.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/439,932 13 January 2003 (13.01.2003) US
- (71) Applicant (for all designated States except US):
CEDARS-SINAI MEDICAL CENTER [US/US];
8700 Beverly Boulevard, Los Angeles, CA 90048 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **KOEFFLER, Phillip, H. [US/US];** 13141 Rivers Road, Los Angeles, CA 90049 (US). **KUMAGAI, Takashi [JP/JP];** 1-2-6-1304, Kumeya, Kita-Ku, Tokyo 115-0043 (JP).
- (74) Agents: **GUY, Pamela, M. et al.;** McDermott, Will & Emery, 4370 La Jolla Village Drive, Suite 700, San Diego, CA 92122 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: PARICALCITOL AS A CHEMOTHERAPEUTIC AGENT

MTT assay

Myeloid Leukemia (Arsenic Trioxide)



(57) Abstract: The invention provides methods of reducing the severity of a proliferative disorder. One method involves administering to an individual having the proliferative disorder an effective amount of paricalcitol, wherein the paricalcitol reduces cellular proliferation, with the proviso that the cancer is not prostate cancer or head and neck squamous cell carcinoma. Another method of reducing the severity of a proliferative disorder provided by the invention involves administering to an individual having the proliferative disorder an effective amount of paricalcitol and an anti-cancer agent, wherein the combination of paricalcitol and the anti-cancer agent reduces cell proliferation, with the proviso that the proliferative disorder is not prostate cancer or head and neck squamous cell carcinoma.

WO 2004/062620 A2



Published:

— *without international search report and to be republished
upon receipt of that report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.